Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Oligometastatic Prostate Cancer (OMPC) | Phase3 | Argentina Australia Austria Belgium Brazil Canada China Czechia France Germany Greece Hungary Israel Italy Japan Malaysia Mexico Netherlands Puerto Rico Singapore Slovakia Spain Switzerland Taiwan United Kingdom United States View all |
NCT05939414 |
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN |
IC-MPGN | Phase3 | Argentina Brazil Canada Czechia Denmark France Germany Greece India Israel Italy Japan Netherlands Poland Slovakia South Korea Spain Switzerland Taiwan Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT05755386 |
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. |
Lymphatic Malformations | Phase2, Phase3 | Argentina Australia Belgium France Germany Italy Netherlands Spain Switzerland United States View all |
NCT05948943 |
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN |
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase3 | Argentina Brazil China France Germany Greece Israel Italy Japan Netherlands Spain Switzerland Turkey (Türkiye) United Kingdom United States View all |
NCT03955445 |
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
Chronic Spontaneous Urticaria | Phase3 | Argentina Canada China Germany Hong Kong Italy Japan Malaysia Netherlands Poland Singapore South Africa Spain Thailand Turkey (Türkiye) United Kingdom United States View all |
NCT05677451 |
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis |
Lupus Nephritis | Phase3 | Argentina Brazil Canada Colombia Estonia France Germany Guatemala Hong Kong Hungary India Italy Lithuania Malaysia Mexico Romania Singapore South Korea Spain Taiwan Thailand United Kingdom United States View all |
NCT05126277 |